Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q1 CY2026, with sales up 4.9% year ...

Q1 earnings beat lifts shares; 2026 guidance narrows as Keytruda grows, Gardasil declines and R&D jumps on deals.

Merck once again suffers the mixed optics from the updated FY2026 adjusted EPS guidance, attributed to the IPR&D charges.

Merck’s widely used immunotherapy, Keytruda, drove the company’s topline growth during the quarter, accounting for nearly ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with ...

Merck MRK reported an adjusted loss of $1.28 per share for the first quarter of 2026, which was narrower than the Zacks ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Performing Dow Stocks So Far in 2026.

MRK is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of MRK shares has increased $0.84 since the market last closed. This is a 0.76% ...

Sandisk, Marvell, and AMD. Please visit Jim Cramer’s 12 Stock Calls: GE Vernova, Arm, and Vertiv, if you’d like to see the ...

Merck (MRK) stock climbed 3% after FDA granted priority review for KEYTRUDA bladder cancer treatment combination, with ...

Merck (MRK)’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence. The factors behind this ...